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PENILAIAN FARMASI DIMULAKAN UBAT PROGRAM 
PENGURUSAN TERAPI DALAM MENINGKATKAN PENYAKIT 
BERKAITAN ILMU, PEMATUHAN UBAT DAN KESIHATAN BERKAITAN 
KUALITI HIDUP DI KALANGAN TYPE 2 PESAKIT DIABETES DI 
SARGODHA, PAKISTAN 
ABSTRAK 
Ubat Program Pengurusan Terapi adalah satu perkhidmatan inovatif, ahli 
farmasi yang diterajui dan menyampaikan yang bercadang untuk menyelesaikan 
masalah terapi dadah, meningkatkan pendidikan pesakit dan meningkatkan 
pematuhan kepada regimen terapeutik. Oleh itu, Kajian ini bertujuan untuk menilai 
kesan ahli farmasi dimulakan Ubat Program Pengurusan Terapi mengenai diabetes 
berkaitan pengetahuan, pematuhan ubat, kawalan glisemik dan Kesihatan Berkaitan 
Kualiti Hidup pencapaian antara Jenis 2 pesakit Diabetes Mellitus di Sargodha, 
Pakistan. Ini adalah satu kajian tiga kali ganda di mana analisis pra-campur tangan 
diabetes pesakit pengetahuan yang berkaitan, pematuhan ubat, kawalan glisemik dan 
status semasa Kesihatan Berkaitan Kualiti Hidup telah dijalankan dengan 
menggunakan alat pra-disahkan. Tiga ratus sembilan puluh dua jenis 2 pesakit 
Diabetes Mellitus telah dimasukkan untuk meneroka atas objektif yang dinyatakan. 
Fasa penilaian pra-campur tangan mendedahkan bahawa peserta kajian mempunyai 
purata pengetahuan diabetes berkaitan (8.02 ± 2.58 daripada 14), pematuhan ubat 
rendah (4.43 ± 1.78 daripada 8), kawalan glisemik miskin (9.44 ± 1.58) dan Kesihatan 
Berkaitan Kualiti Hidup (0,4715 ± 0,336 dan 64,77 ± 6,57). maka lain pengetahuan 
dan pematuhan ubat, sederhana korelasi yang signifikan (r <0.3, p <0.05) diperhatikan 
di kalangan semua pemboleh ubah bersandar. Analisis pra-campur tangan diikuti 
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dengan rawak peserta kajian dan pelaksanaan campur tangan pendidikan oleh ahli 
farmasi. Data yang post campur tangan telah disediakan dari 161 mata pelajaran 
kumpulan campur tangan dan 164 peserta dalam kumpulan kawalan. Diabetes 
pengetahuan yang berkaitan, pematuhan ubat dan Kesihatan Berkaitan Kualiti skor 
Life dikaitkan dengan ketara (p <0.001) apabila kumpulan campur tangan dan 
kumpulan kawalan dibandingkan pada akhir campur tangan. Terdapat peningkatan 
dalam skor diabetes berkaitan pengetahuan (10.55 ± 2.56), skor pematuhan ubat (5.24 
± 1.48) dan Kesihatan Berkaitan Kualiti Hidup (0,6115 ± 0,286 dan 68,37 ± 14,094) 
di kalangan peserta kumpulan campur tangan. min HbA1c bermakna dikurangkan 
kepada 8.97 ± 1.362. Tambahan pula, perbezaan yang signifikan (p <0.05) juga 
diperhatikan di antara sebelum dan kumpulan intra pasca (lengan intervensi) juga 
dilaporkan. Kesimpulannya, kajian ini menunjukkan bahawa ahli farmasi dimulakan 
Ubat Program Pengurusan Terapi memberi kesan positif kepada hasil terapeutik 
dipilih. Oleh itu, peranan ahli farmasi dalam pendidikan pengurusan diri pesakit mesti 
diiktiraf sebagai sebahagian penting dalam sistem penjagaan kesihatan dan mesti 
dipupuk untuk menggalakkan konsep kualiti penjagaan. 
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ASSESSMENT OF PHARMACIST INITIATED MEDICATION THERAPY 
MANAGEMENT PROGRAM IN IMPROVING DISEASE RELATED 
KNOWLEDGE, MEDICATION ADHERENCE AND HEALTH RELATED 
QUALITY OF LIFE AMONG TYPE 2 DIABETIC PATIENTS IN     
SARGODHA, PAKISTAN 
ABSTRACT 
The Medication Therapy Management Program is an innovative, pharmacist-
led and delivered service that intends to resolve drug therapy problems, enhance 
patient education and improve adherence to the therapeutic regimen. The present 
study was therefore aimed to assess the impact of pharmacist initiated Medication 
Therapy Management Program on diabetes related knowledge, medication adherence, 
glycemic control and Health Related Quality of Life outcomes among Type 2 
Diabetes Mellitus patients in Sargodha, Pakistan. This was a three phase study 
whereby a pre-intervention analysis of patients’ diabetes related knowledge, 
medication adherence, glycemic control and present status of Health Related Quality 
of Life was undertaken by using pre-validated tools. Three hundred and ninety two 
Type 2 Diabetes Mellitus patients were included to explore above stated objectives. 
The pre-intervention assessment phase revealed that study participants had average 
diabetes related knowledge (8.02±2.58 out of 14), low medication adherence 
(4.43±1.78 out of 8), poor glycemic control (9.44±1.58) and Health Related Quality of 
Life (0.4715±0.336 and 64.77±6.57). Other than knowledge and medication 
adherence, moderate significant correlations (r<0.3, p<0.05) were observed among all 
dependent variables. The pre-intervention analysis was followed by randomization of 
xx 
 
the study participants and implementation of the educational intervention by the 
pharmacist. The post intervention data were available from 161 subjects of 
intervention group and 164 participants in the control group. Diabetes related 
knowledge, medication adherence and Health Related Quality of Life scores were 
significantly associated (p<0.001) when intervention group and control group were 
compared at the end of the intervention. There was an increase in diabetes related 
knowledge score (10.55±2.56), medication adherence score (5.24±1.48) and Health 
Related Quality of Life (0.6115±0.286 and 68.37±14.094) among the participants of 
intervention group. The mean HbA1c mean reduced to 8.97±1.362. Furthermore, a 
significant difference (p<0.05) was also observed between the pre- and post- intra 
group (interventional arm) was also reported.  In conclusion, the present research 
demonstrated that pharmacist initiated Medication Therapy Management Program had 
a positive impact on selected therapeutic outcomes. Therefore, the role of pharmacists 
in patient self-management education must be recognized as an integral part of the 
health care system and must be promoted to promote the concept of quality of care. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background of the study 
Since its earliest description several thousand years ago, Type II Diabetes mellitus 
(T2DM) has remained a chronic and progressive disease (Montenero, 2000). Over a 
period of decades, although the ability of diagnosis and treatment of diseases has 
significantly improved, the disease profile of the world has also altered at a 
frightening rate (Centers for Disease Control Prevention, 2006). Chronic diseases 
which include cardiovascular diseases, stroke, cancers, chronic respiratory diseases, 
diabetes and mental disorders are now accounted for 47% of the global burden of 
diseases and 60% of all deaths worldwide (World Health Organization, 2003).  
Within this context, T2DM is a serious concern with an increasing prevalence around 
the globe (Tabish, 2007). T2DM is a complicated and overwhelming condition-
affecting people of all ages and ethnic groups.  In 2003, 194 million of the population 
had T2DM and almost three-quarters of them were living in the developing world 
(Narayan et al., 2006).  The increasing number of people with type 2 diabetes is a 
worldwide concern, but the major part of this numerical increase will occur in 
developing countries. The increase in prevalence of diabetes in developing countries 
is projected to be 170%  compared to 42% in developed countries. (Wild, Roglic, 
Green, Sicree, & King, 2004). Furthermore, almost 1 million casualties were reported 
each year because of T2DM and two-thirds of these were reported from the 
developing countries (World Health Organization, 2002). Population growth, ageing 
issues, dietary changes, urbanization, increased prevalence of obesity and poor 
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physical  inactivity were the major factors towards an increased incidence of T2DM 
(Hu, 2011). By 2025, it was anticipated that this figure will be expanded by 72%; 333 
million new cases will be reported and the prevalence will be increased to double fold 
in the  Middle East, North Africa, South Asia and Sub-Saharan African regions 
(World Health Organization, 2002). In line to what is reported, the prevalence of 
T2DM and its adverse effects were more noticeable in South Asia when contrasted 
with the other area of the world (Ghaffar, Reddy, & Singhi, 2004). In South Asia, 
large number of individuals live on or below the poverty line and have lack of access 
to health care facilities. There are no national welfare plans and provision of medical 
coverage for the poor people (Khowaja, Khuwaja, & Cosgrove, 2007). The poor 
people cannot bear to pay for health care facilities, therefore, the individuals are 
diagnosed belatedly resulting in  acute and chronic complications (Danaei et al., 
2011).  
1.2 Overview of Pakistan’s health care system  
National public health is a recent innovation in Pakistan. National health planning 
began with the Second Five-Year Plan (1960-65) and continued through the Eighth 
Five-Year Plan (1993- 98). In addition to public- and private-sector biomedicine, 
there are indigenous forms of treatments. Some manufactured remedies are also 
available in certain pharmacies. Homeopathy is also taught and practiced in Pakistan. 
Prophetic healing is based largely according to the teaching of the Prophet pertaining 
to hygiene and moral and physical health, and simple treatments are used, such as 
honey, a few herbs, and prayers. Some religious conservatives argue that reliance on 
anything but prayers suggests lack of faith, while others point out that the Prophet 
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remarked that ‘Allah has provided cure for every disease other than death and old age’ 
(CIA, 2005;WHO, 2007). 
1.3 Structure and health services in Pakistan  
The Ministry of Health is responsible for all matters concerning national planning and 
coordination in the field of health. The Drugs Control Organization is a subsidiary of 
Ministry of Health. It facilitates local pharmaceutical units and drug importers in 
registration and licensing and making their participation possible in various events 
organized the world over (MOH, 2008).   
Under the Pakistani constitution, the federal government is responsible for planning 
and formulating national health policies and provincial governments for its 
implementation. The private sectors serve nearly 70% of the population, whereas 
public sector comprises more than 10,000 health facilities ranging from Basic Health 
Units (BHUs) to tertiary referral centers. BHU covers around 10,000 people, whereas 
a larger Rural Health Center (RHCs) covers around 30000-450000 people. In Pakistan 
Primary Health Center (PHC) units comprises both BHUs and RHCs. The Tehsil 
Headquarters Hospital (THQ) covers the population at sub-district level whereas 
District Headquarters Hospital (DHQ) serves at district level as its name suggests 
(Ghaffar et al., 1999). Health system of any country is mainly based on the human 
resources available. As in case of Pakistan, there is a lack of clear long-term vision for 
human resource development and the Ministry of Health, both at federal and 
provincial levels do not have a unit responsible for such an important health system 
function. The health information system is fragmented. Each vertical program has 
more or less its own information system and none covers the private health sector. 
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There is no organized system of disease surveillance and there is limited capacity to 
use information for decisions. The overall capacity to undertake health policy and 
system research is deficient (WHO, 2007). 
As the population is growing and there are issues of poor housing, lack of exercise, 
pollution, improper diet and the lack of health education, diseases are rampant. The 
health care system in Pakistan has been confronted with problems of inequity, scarcity 
of resources, inefficient and untrained human resources, gender insensitivity and 
structural mismanagement (Babar, 2006). Pakistan is facing a very precarious 
economic situation and there is a need of innovative health reforms (Islam, 2002). 
Political instability caused frequent changes in the government, thus resulting 
corresponding changes of health policy. Till now, health policies have not been given 
enough time for proper implementation in the country  (Khan & Heuvel, 2007). The 
low priority given to the health sector by the military regimes has resulted in a 
persistent contrast between reasonable economic growth and government expenditure 
on health (MOF., 2009). 
1.4 Role of pharmacists in different sectors in Pakistan 
It has been estimated that around 8102 pharmacists are present in Pakistan, 2836 work 
in public sector, 5023 in private setting while 243 pharmacists in total private non-
profit organizations (WHO, 2007). Approximately 55% are engaged in production of 
pharmaceuticals, 15% in the federal and provincial drug control and hospital 
pharmacy setup, 15% in the sales and marketing of pharmaceuticals, 10 % in 
community pharmacy, 5% in teaching and research. Pharmacy education is mainly 
focused on the industrial need, as a result, at present; a large number of pharmacists in 
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Pakistan are involved with the pharmaceutical industry. Although the world over, the 
role of pharmacists is recognized in community pharmacies, hospitals and drug 
regulatory authorities but the health care system of Pakistan has yet to recognize this 
role (Babar, 2007).  
1.5 Diabetes in Pakistan 
Pakistan is a South-Asian country with a population of approximately 150 million 
(69% of the population are rural, over an area of 800,000 km
2
). Pakistan is a low-
income country with limited resources (Baig et al., 2013). Pakistan was placed 
amongst the top ten nations of the world with the highest number of individuals with 
T2DM in 2004 and was anticipated that an expected 14.5 million people of  Pakistan 
will have T2DM by the year 2025 (Sarah, Gojka, Anders, Richard, & Hilary, 2004). 
T2DM affects both high and low-income group; 12% of individuals above 25 years of 
age suffer from T2DM and 10% people have impaired glucose tolerance (IGT), which 
is expected to increase more swiftly in the future (Hakeem & Fawwad, 2010; Shera et 
al., 1995). Recently, it was reported that there were approximately 6.6 million 
Pakistani adults with T2DM in 2012 (Kalra, Peyrot, & Skovlund, 2013). In Pakistan, 
prevalence of newly diagnosed diabetes was 5.1% in male and 6.8% in female in 
urban areas and 5.0% in men and 4.8% in women in rural regions (Aziz, Hossain, & 
Siddiqui, 2009).  
Even though, T2DM has reached epidemic proportions worldwide, the number of 
affected individuals is expanding at a much faster rate than was formerly anticipated 
(Makrilakis & Katsilambros, 2003). Previously, T2DM was considered as a disease of 
ageing and the elderly but now this perception has turned out to be a complete 
6 
 
misconception and individuals with type 2 diabetes mellitus in developing nations, 
including Pakistan are presented at a younger age (Shera, Jawad, & Maqsood, 2007). 
Acceleration in rates of T2DM in Pakistan is posing threats to the economy and 
quality of life of individuals due to poor glycemic control and very high rates of 
complications (Basit, Hydrie, Hakeem, Ahmedani, & Masood, 2004; Khoharo & 
Qureshi, 2008; Moin, Gondal, & Bano, 2008).  
1.6 Diabetes care in Pakistan 
There is no cure for T2DM, but the condition is controllable with a combination of 
medical care, patient education and self-management (American Diabetes 
Association, 2009). Diabetes complications present a considerable burden of 
morbidity and mortality, with the danger of both macrovascular and microvascular 
complications (UK Prospective Diabetes Study Group, 1998).  
Multiple diabetes complications in Pakistani patients with T2DM have been reported 
in literature. A study highlighted that 21% of individuals with T2DM suffer from 
macrovascular complications which include angina pectoris, myocardial infarction 
and stroke (17%, 5% and 2.6%, respectively) and microvascular complications, 
including 43% retinopathy, 39.6% neuropathy, 20.2% nephropathy and 4% foot ulcers 
(Shera et al., 2004). Previous studies on T2DM in Pakistan reported that a large 
proportion of patients with T2DM had poor or suboptimal glycemic control and the 
mean glycated hemoglobin (HbA1c) was higher than the  prescribed level as per 
international guidelines (Badruddin, Basit, Hydrie, & Hakeem, 2002; Khattab, 
Khader, Al-Khawaldeh, & Ajlouni, 2010; Mahmood & Aamir, 2005; Zuberi, Syed, & 
Bhatti, 2011). Additionally, the medical care cost is projected to be very high 
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(Khowaja et al., 2007). Resource imperatives society, lack of medical repayment and 
inadequate allocation of health care budget are barriers to quality  medical care 
whereby the vast majority of the patients are unable to bear the high cost of treatment 
(Govender, Ghaffar, & Nishtar, 2007; Khuwaja, Khowaja, & Cosgrove, 2010). 
Institutions specializing in diabetes care are limited in number and are concentrated in 
the big cities. There is no personnel support and very few specialized dieticians and 
pharmacists are available for the patients (Jawad, 2003). Family physicians have little 
time (the average time spent with a person with diabetes was 8.5 minutes) for 
counselling that makes issues more complicated for the patients (Shera, Jawad, & 
Basit, 2002). 
1.7 T2DM-related knowledge and Diabetes Self-management Education  
A low level of T2DM-related awareness within the population and a low priority to 
initiate an appropriate preventive and curative plan have been recognized as major 
issues in the management of T2DM (Ooyub, Ismail, & Daud, 2004). Poor T2DM-
related knowledge and management skills among patients is frequently reported in 
literature (Al Shafaee et al., 2008; Angeles-Llerenas, Carbajal-Sánchez, Allen, 
Zamora-Muñoz, & Lazcano-Ponce, 2005; Bell, Passaro, Lengerich, & Norman, 1997; 
Bruce, Davis, Cull, & Davis, 2003; Çaliskan, Ozdemir, Ocaktan, & Idil, 2006; Gunay 
et al., 2006; Habib & Aslam, 2003; Kamel, Badawy, El Zeiny, & Merdan, 1999; 
McClean, McElnay, & Andrews, 2001; Murata et al., 2003; Murugesan, Snehalatha, 
Shobhana, Roglic, & Ramachandran, 2007; Speight & Bradley, 2001; West & 
Goldberg, 2002). Additionally, another key element of effective disease management 
for T2DM is the support of patients’ self-management capacity building. In order to 
achieve optimal health, T2DM patients are usually advised strict, rigorous and 
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permanent lifestyle changes that include dietary interventions, physical activity, strict 
adherence to medication regimes, good metabolic control and  regular medical 
examinations of eyes, foot and kidney (Khan et al., 2012). However, if patients do not 
adhere to these guidelines, their diabetes is more likely to be poorly controlled with an 
increased risk of developing further health problems. Therefore, adherence is a key 
factor associated with the effectiveness of all pharmacological therapies and foremost 
the most important factor for medications prescribed for chronic conditions like 
T2DM (Osterberg & Blaschke, 2005). Consequently, among different strategies for 
diabetes control, improving adherence plays a key role in optimizing metabolic 
control (Albano, Crozet, & d’Ivernois, 2008; Lindenmeyer et al., 2006).  
Furthermore, to overcome the poor acquaintance towards T2DM, Diabetes Self-
management Education (DSME) is considered an integral part of care for individuals 
who want to achieve successful outcomes (Haas et al., 2013). T2DM needs lifetime 
care and management; however, 50–80% of patients with T2DM do not posses 
enough skills and knowledge for self-care of the disease (Clement, 1995). A study 
reported that the 62.6% of the diabetic population of Pakistan had a poor level of 
awareness regarding T2DM and its management (Mahmood et al., 2011). Monitoring 
of metabolic markers, i.e. blood pressure, body weight, lipid profile, blood glucose 
and HbA1c are is essential in clinical management as hypertension, obesity, and 
dyslipidemia are well-known risk factors of atherosclerosis and are frequently 
reported among diabetic patients (Tripathi & Srivastava, 2006). Previous studies have 
shown that DSME programs improve homeostasis of metabolism and healthy 
lifestyles prevent the development of atherosclerosis in patients with T2DM (Kim et 
al., 2006; Mulnier et al., 2013). Therefore, diabetes education is considered to be an 
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essential element in reaching a good glycemic control (Berger & Mühlhauser, 1999). 
However, in real practice, modest improvements in glycemic control have been found 
after the educational intervention focused on diabetes patients (Farsaei, Sabzghabaee, 
Zargarzadeh, & Amini, 2010; Koev, Tankova, & Kozlovski, 2003; Wens et al., 2008). 
Centrally focused interventions without the inputs of pharmacists or nurses, patients’ 
non-involvement, poorly structured programs and non-need assessments are among 
the few reasons of the failure of T2DM-related interventions (Jimmy & Jose, 2011). 
Therefore, it is now established that a well-structured health education program with 
the involvement all healthcare professionals and a prior need assessment is necessary 
for the improvement of diabetes-related outcomes in term of glycemic control and 
other metabolic complications (Pal, Pal, Barua, & Ghosh, 2010). 
1.8 Rationale of the study 
T2DM management is a lifelong process that requires efforts from diabetic healthcare 
providers and patients. However, T2DM Individuals themselves are a key factor in the 
successful management of the disease and prevention of serious complications (Haas 
et al., 2013). Diabetes self-care requires patients to adapt dietary and lifestyle 
modifications, regular blood glucose monitoring and appropriate medication intake 
with the help of healthcare providers for maintaining a higher level of self-confidence 
leading to successful behavioural change (Funnell & Anderson, 2004; UK Prospective 
Diabetes Study Group, 1998). In developing countries like Pakistan, the emergence of 
this pandemic at an early age is attributable to rapid cultural changes and a high 
degree of urbanization leading people to adopt unhealthy lifestyles and decreased 
physical activity. The obesity along with a sedentary lifestyle and increase in caloric 
intake played a major role in the recent explosion of this chronic illness (Iqbal, 2007). 
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Non adherence to the prescribed treatment regimen is common in patients with 
diabetes ranging from 23-77%, making optimal glycemic control difficult to achieve 
(Riaz, Basit, Fawwad, Ahmedani, & Rizvi, 2014).  
Therefore, it is important to explore the patients’ perception about T2DM, its 
management and interaction between patients and healthcare providers. It is also 
essential to understand the contribution of general T2DM diabetes knowledge among 
patients and their adherence to medication in order to promote better self-care for 
T2DM. Within this context, it is recommended that T2DM-related education should 
be promoted through a pharmacist led medication therapy management (MTM) 
program (Johannigman et al., 2010; S. L. Pinto, Bechtol, & Partha, 2012). A unique 
attribute of MTM program is the engagement of the pharmacist in a wider set of 
activities other than simply counselling about the disease and medications.  
1.9 Significance of the study 
The incidence and prevalence of T2DM continues to grow worldwide and  requires 
continuous medical care and patient self-management education to prevent acute 
complications and to reduce the risk of long-term complications (American Diabetes 
Association, 2009). The importance of glycemic control in reducing future 
complications in T2DM is highly related to medication adherence and T2DM-related 
knowledge (Browne, Avery, Turner, Kerr, & Cavan, 2000; Okuno et al., 1999). 
Therefore, the assessment of the patient’s disease-related knowledge and medication 
adherence is important for better therapeutic outcomes (Rothman et al., 2003). 
This study, therefore, will attempt to explore the association between patients’ 
diabetes-related knowledge, medication adherence, glycemic control and its effect on 
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Health Related Quality of Life (HRQoL). Based on the results, a pharmacist-led 
MTM program will be offered to T2DM patients attending public health facilities in 
Sargodha city, Pakistan. It is hoped that the MTM will optimize therapeutic outcomes 
by reducing drug associated adverse events, improved medication adherence and 
increased patients’ understanding of their diseases and prescribed drugs. In this study, 
healthcare professionals and policy makers will have a clear  picture of T2DM-related 
problems and will help in planning and developing didactic programs for patients in 
the near future.  
1.10 Study objectives 
The primary objective of this study is to evaluate the effectiveness of a pharmacist-led 
MTM program to control and minimize T2DM-related complications by improving 
diabetes-related knowledge, medication adherence, glycemic control and HRQoL. In 
addition, the secondary objectives of this study are as under: 
1. To assess diabetes-related knowledge, HRQoL, medication adherence and 
glycemic control among T2DM patients attending a public healthcare institute in 
Sargodha, Pakistan.  
2. To assess the relationship between diabetes-related knowledge, medication 
adherence, HRQoL and HbA1c. 
3. To implement a pharmacist-led MTM program focusing to improve diabetes-
related knowledge, medication adherence, glycemic control and HRQoL among 
the study population.  
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4. A post- evaluation to assess the  effectiveness of the pharmacist-led MTM 
program. 
1.11 Thesis overview 
In this thesis, chapter 2 reviews the literature related to the study with the definition of 
key terms and provides a conceptual framework for the study. A brief discussion of 
the importance of diabetes related knowledge, medication adherence, glycemic 
control and HRQoL is also presented. The literature review finishes with conclusion 
stating that a pharmacist-led intervention through  MTM has the potential to improve 
medication adherence in diabetes and to reduce levels of HbA1c and other 
biochemical parameters. A thorough review of literature relevant to the study, 
concentrating on patient education, medication adherence, glycemic control and 
HRQoL among T2DM patients forms the bulk of this chapter. 
Chapter 3 starts with a systematic discussion of the methodology used for conducting 
the study. The tools used for data collection, randomization of patients, and 
implementation of intervention through the MTM program is thoroughly discussed.  
Chapter 4 demonstrates the assessment of diabetes-related knowledge, medication 
adherence, glycemic control and HRQoL among T2DM patients. The detailed 
methodology, findings and conclusions of the assessment of patient knowledge about 
diabetes, medication adherence, glycemic control and HRQoL is described.  
Chapter 5 illustrates the pre- and post- interventional assessment of diabetes related 
knowledge, medication adherence, glycemic control and HRQoL and the impact of 
the intervention is evaluated.   
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Chapter 6 includes the conclusions of the thesis and along with a set of 
recommendations for further research work. 
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CHAPTER 2 
PHARMACISTS’ INTERVENTIONS TO IMPROVE CONTROL AND 
MANAGEMENT IN TYPE 2 DIABETES MELLITUS: LITERATURE 
REVIEW  
2.1 Introduction 
T2DM is a metabolic disorder characterized by chronic hyperglycemia, polyuria, 
polydypsia, polyphagia, emaciation, and weakness due to disturbances in 
carbohydrate, fat, and protein metabolism, which are associated with an absolute or 
relative deficiency in insulin secretion and/or insulin action (Balkau & Eschwege, 
2003; Deb & Dutta, 2006; Expert Committee on the Diagnosis and Classification of 
Diabetes Mellitus, 1997; Kumar. P, 2002; Lindberg G, Lindblad U, & Melander A, 
2004). 
Diabetes is the most well-known endocrinal disorder, and as of the year 2010, it was 
evaluated that more than 200 million individuals worldwide had T2DM with 300 
million subsequently to have the diabetes by 2025 (Amos, McCarty, & Zimmet, 1997; 
King, Aubert, & Herman, 1998; Zimmet, 2000).  Diabetes may be categorized into 
several types, but the two major types are type 1 and type two (Zimmet, Cowie, Ekoe, 
& Shaw, 2004). Table 1 contrasts the features of type 1 and type 2 DM (H., 2010). 
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Table 2.1: Contrasting Features of Type 1 and Type 2 Diabetes Mellitus 
(Tripathi, 2006) 
 
Features Type 1 Type 2 
Frequency 
a 
10-20% 80-90% 
Age of onset Early below 35 years Late after 40 years 
Type of onset Abrupt and severe Gradual and insidious 
Weight Normal Obese or non-obese 
*HLA (human 
leukocyte antigen) 
Linked to 
^
DR3, 
HLA DR4,HLA DQ 
No HLA association 
Family history < 20% About60% 
Genetic locus Unknown Chromosomes 6 
Diabetes in 
identical twins 
50% concordance 80% concordance 
Pathogenesis Autoimmune 
destruction of β cells 
Insulin resistance impaired 
insulin secretion 
Islets of cell 
antibodies 
Yes No 
Blood insulin level Decreased insulin Normal or increased insulin 
Islet-cell changes Insulin cell depletion No insulitis, later fibrosis 
Amyloidosis Infrequent Common in chronic cases 
Clinical 
management 
Insulin, diet Diet, exercise, oral drugs, 
insulin 
Acute 
complications 
Ketoacidosis Hyperosmolar coma 
*HLA: Human Leukocyte Antigen 
^HLA-DR3: Human Leukocyte Antigen - antigen D Related,  
^HLA-DR4: Human Leukocyte Antigen - antigen D Related 
^HLA-DQ: is a cell surface receptor protein found on antigen presenting cells 
a
Proportion of sample from the population 
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2.2 Type 1 Diabetes 
β-Cell destruction happens in pancreatic islets. Most of the cases include autoimmune 
antibodies that destroy β-cells and that are detectable in the blood, but some cases are 
idiopathic. In all type 1 diabetes  cases, levels of circulating insulin are low or very 
low, and patients are more susceptible to ketosis. This type is less common and has a 
low degree of genetic predisposition. 
2.3 Type 2 Diabetes 
Either a β-cell mass does not exist or a moderate reduction has occurred. The insulin 
in circulation is low or normal, but can be high. No anti-β-cell antibodies are 
demonstrable, and the DM has a high rate of late onset in patients’ lives. More than 
90% of cases of diabetes are type 2 DM (KD, 2007).  
2.4 Pharmacist’ intervention in diabetes management 
To reap the benefits of advanced medical treatments, more efficient and effective 
interventions are required to help individuals in following medical regimens (Haynes, 
McDonald, Garg, & Montague, 2002). Recently, interest has been increasing in 
extending the role of the pharmacist in public health, beyond the traditional product 
orientated functions of dispensing and distributing medication (O'Loughlin, Masson, 
Déry, & Fagnan, 1999). The pharmacy profession is increasingly being recognized as 
having a strategic position in health promotion, due to their in-depth knowledge of the 
rational use of medicines (Olsson, Tuyet, Nguyen, & Lundborg, 2002). The role of the 
pharmacist as part of a multidisciplinary approach cannot be overemphasized. 
Pharmacists are now a critical part of health care teams, and they are taking more 
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responsibility for clinical outcomes of drug therapy (Narhi, Airaksinen, Tanskanen, & 
Erlund, 2000).  
A number of limitations exist in the potential role of pharmacists, such as their lack of 
prescribing power and a shortage in some countries of suitably qualified pharmacists 
with clinical experience. These issues may be further compounded by economic 
constraints, particularly in developing countries. Adherence to therapy is also a vital 
component of any medication regimen, and pharmacists are ideally positioned at the 
interface between the patient and his or her medicine to influence medication 
adherence in a positive manner (Bogden, Abbott, Williamson, Onopa, & Koontz, 
1998).  
The World Health Organization expressed, “pharmacists have a critical role to play, 
which is considerably more than selling medicines” hence addressing the problem of 
low adherence to long-term therapy for chronic conditions (World Health 
Organization). The organization summarized its view, indicating that the pharmacist’s 
role fits the 7-star concept, in which the pharmacist is described as a caregiver, 
communicator, decision-maker, teacher, lifelong learner, leader, and manager and, 
thus, is perfectly positioned to carry out effective interventions. These roles enable 
him/her to carry out interventions successfully, improving the effectiveness of drug 
therapy, reducing costs, preventing undesirable side effects, and improving clinical 
outcomes for patients (Dorevitch & Perl, 1996). Increasingly, it is being accepted that 
pharmacists are well equipped and well trained to provide interventions for chronic 
conditions. Intervention programs involving the community pharmacist are one of the 
few techniques that have proven successful, generating benefits that are 10 times 
greater than the costs (I Côté, Moisan, Chabot, & Grégoire, 2005). All of the roles that 
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a pharmacist can play as part of a multidisciplinary team depend on the pharmacist 
being suitably qualified in a number of competencies, which may not always be the 
case, especially in developing countries. Evidence has shown that pharmacist 
involvement in managing therapeutic regimens through a medication therapy 
management (MTM) program for populations of patients with complex chronic 
diseases such as diabetes, hypertension, (Cranor, Bunting, & Christensen, 2003) heart 
failure, (M. D. Murray, Ritchey, Wu, & Tu, 2009; M. D. Murray et al., 2007) and 
hypercholesterolemia (Bunting & Cranor, 2006) results in better clinical outcomes. 
MTM is a pharmacist led professional service aimed at reducing drug associated 
adverse events, improving patient medication adherence, and increasing patient 
understanding of their diseases and prescribed drugs. MTM “is a distinct service or 
group of services that optimizes therapeutic outcomes for individual patients” 
(American Pharmacists Association National Association of Chain Drug Stores 
Foundation, 2008).  
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Figure 2.1: Outlines of the core elements of MTM services and how MTM 
integrates with other health care providers and the final recipient of the care 
process—the patient (Hussein & Brown, 2012). 
 
Therefore, the current review examines the contributions of pharmacists to the 
improvement of the long-term prognoses of patients with DM by improving its 
control and management. It is the authors’ hypothesis that pharmacists can play a 
major role in reducing HbA1c and improving both glycemic control and HRQoL.  
The search terms were diabetes mellitus and pharmacist intervention. All available 
years in each database were searched. The studies included in this review were 
identified through a search of Cochrane Library Databases, Medline, EMBASE, 
PsychINFO, ERIC, Dissertation, and PubMed. Only papers that were published in 
English and that used human participants were considered. An initial search, using the 
above terms in searches of abstracts, identified 35 published articles. Full texts of all 
articles were obtained and independently read in full by the authors to identify those 
papers suitable for inclusion in this review. Studies that took place in the community, 
outpatient, primary care, and hospital (secondary care) settings were all included. 
Randomized controlled trials and retrospective cohort reviews were included. Using a 
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Microsoft Excel spreadsheet, data were extracted from the chosen studies. No 
blinding regarding a journal or author was done. Data were extracted for authors, year 
of publication, randomization quality criteria, patient details, intervention details, 
endpoint and outcome measures, baseline and post intervention results, and main 
findings. To assess the methodological quality of the described studies, we noted how 
the randomization and allocation concealment were conducted. 
2.5 Interventional effects on HbA1c, lipids, and the cardiovascular System 
Diabetic patients with concomitant dyslipidemia are often soft targets for 
cardiovascular disease and deaths. An early intervention to normalize circulating 
lipids has been shown to reduce cardiovascular morbidity and mortality. HbA1c is 
routinely used as a marker to indicate long-term glycemic control. The American 
Diabetes Association estimated the risk of diabetes related mortality increased 25% 
for each 1% increase in HbA1c. A strong correlation has been shown between lipid 
profile and coronary artery disease. One study lasting 12 months with 228 diabetic 
patients at 7 independent pharmacies in Lucas County, Ohio, was conducted to 
evaluate the management of medication therapy. In the study, their pharmacists 
counselled patients at 6-month intervals regarding their diets and lifestyle 
modifications, including smoking cessation and adherence to exercise plans. The 
measured outcomes included HbA1c and systolic blood pressure (SBP). Because of 
the interventions, means (±SD) HbA1c values reduced from 7.08 ± 1.54% to 6.89 ± 
1.30% at 12 months. Patients with an HbA1c level more than 7% at baseline averaged 
a decrease of 0.5% at 6 months and 0.75% at 12 months and SBP became normal. 
Caffeine,  liquor consumption, and smoking decreased and physical activity increased 
(S. L. Pinto, Bechtol, & Partha, 2011).  
21 
 
A 6-month randomized controlled trial was conducted at the endocrine clinic at 
Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Malaysia. Type 2 
diabetes mellitus patients (n = 73) attending an endocrine clinic at Universiti 
Kebangsaan Malaysia Medical Centre (UKMMC) were randomized to either control 
(n = 36) or intervention group (n = 37) after the screening. Patients in the intervention 
group received an intervention from a pharmacist during the enrollment, after three 
and six months of the enrollment. Outcome measures such as HbA1c, BMI, lipid 
profile, Morisky scores and quality of life (QoL) scores were assessed at the 
enrollment and after 6 months of the study in both groups. Patients in the control 
group did not undergo intervention or educational module other than the standard care 
at UKMMC. The HbA1c values reduced significantly from 9.66% to 8.47% 
(P = 0.001) in the intervention group. However, no significant changes were noted in 
the control group (9.64–9.26%, P = 0.14). BMI values showed significant reduction in 
the intervention group (29.34–28.92 kg/m2; P = 0.03) and lipid profiles were 
unchanged in both groups. Morisky adherence scores significantly increased from 
5.83 to 6.77 (P = 0.02) in the intervention group; however, no significant change was 
observed in the control group (5.95–5.98, P = 0.85). HRQoL profiles produced mixed 
results (Butt, Ali, Bakry, & Mustafa, 2015). 
A 6-month randomized, controlled, parallel-group trial with 135 diabetic patients was 
conducted in Belgium to assess the effectiveness of community pharmacist 
interventions in diabetic care. Patients at 66 community pharmacies were randomly 
assigned to receive a pharmacist’s care. The interventions mainly focused on correct 
use of medication, medication adherence, healthy lifestyle promotion, and changes in 
pharmacotherapy (i.e., type and/or dose of hypoglycemic agents). The results showed 
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a significant reduction (1.05%) in HbA1c in those patients whose pharmacotherapy 
plans were changed by a pharmacist’s intervention (Mehuys et al., 2011). 
To evaluate the effectiveness of a diabetes-care management program, 179,249 
patients at Kaiser Permanente Northern California with diabetes were enrolled in 
another study. In the 32-week study, patients were divided into 2 groups, one of 
which was monitored after 12 and 24 weeks under a managed care program, whereas 
the other group acted as controls. Pre- and post-program, HbA1c levels, lipid profiles, 
and SBPs were compared between groups. It was found that a statistically significant 
decrease in levels of HbA1c and low density lipoprotein cholesterol (LDL) occurred 
in patients who participated in the managed care program (Schmittdiel, Uratsu, 
Fireman, & Selby, 2009). 
To evaluate the effects of medication management in patients having diabetes and 
hypertension, a randomized control trial of 36 weeks, with 52 patients from Tulsa, 
Oklahoma assessed the interventions of community pharmacists in patients’ therapies. 
The intervention group participants received MTM services for hypertension and 
diabetes management on a monthly basis. The mean intervention group SBP 
decreased 17.32 mm Hg, whereas the mean control group SBP level increased 2.73 
mm Hg (p = 0.003). The percentage of patients at goal BP increased from 16.0% to 
48.0% in the intervention group and decreased from 20.0% to 6.67% in the control 
group. Intervention group participants were 12.92 times more likely than control 
group participants to achieve goal BP (p = 0.021). Although the mean adherence rate 
in the intervention group increased 7.0%, while remaining fairly constant in the 
control group (-0.7%), this group difference was not statistically significant (Planas, 
Crosby, Mitchell, & Farmer, 2009).  
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A 53-week study was conducted with 43 patients at Penang Hospital in Malaysia to 
evaluate a Diabetes Medication Therapy Adherence Clinic (DMTAC) managed by 
pharmacists. Patients having HbA1c of more than 8% were included in the study. The 
patient’s demographics, medication regimens, and adherence to therapy were 
evaluated, and the pharmacists’ 6-week interventions were reviewed. HbA1c, fasting 
blood glucose (FBG), LDL, triglycerides (TG), and high-density lipoprotein (HDL) 
cholesterol was evaluated. A mean reduction in HbA1c of 1.73% (p < 0.001), mean 
reduction in FBG, and a mean reduction in LDL cholesterol of 0.38 mmol/L (p = 
0.007) was achieved. The difference in TG and HDL cholesterol were not significant. 
Patient adherence to medication regimens improved significantly with an increase in 
the mean MMMAS score from 7.00 to 10.84 (p < 0.001) after completion of the 
DMTAC program (Phei Ching & Kelvin, 2010).  
In a study intended to evaluate the clinical pharmacist’s role in a multidisciplinary 
health care team, which included physicians, clinical pharmacists, registered nurses, 
and a registered dietician, diabetic patients in multispecialty ambulatory care medical 
group in suburban Chicago were seen by clinical pharmacists for interventions; 
education, initiation, or adjustment of pharmacotherapy plans; and ordering of 
pertinent laboratory tests. A substantial drop in HbA1c levels occurred, which 
exhibited that the involvement of a pharmacist in a health care professional team 
could improve patient results (Brooks, Rihani, & Derus, 2007).  
To assess clinical outcomes for patients with DM who received medication 
management every 2 to 6 weeks as determined by the severity of their illness or level 
of educational need from a pharmacist. Once the initial goals were met, a patient 
would be asked to return in 3 to 6 months for a follow-up appointment. A 1.5-year 
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study was conducted in collaboration with private physicians. Patients who were older 
than 18 years of age and who had type 1 or type 2 DM were included in this study. 
HbA1c, body weight, and BP were observed at 3 intervals. A significant reduction in 
HbA1c was found, but no changes in BP or reductions in weight were observed 
(Nkansah, Brewer, Connors, & Shermock, 2008).  
Recently, a 53-week study was conducted in Massachusetts to evaluate the outcomes 
of implementation of a pharmacist-supervised at the Veterans Affairs diabetic clinic. 
A total of 160 T2DM patients who were taking either an oral hypoglycemic 
medication or insulin, were included in the study. The patients met with pharmacist 
after 12 weeks for review of clinical outcomes. A mean reduction of more than 1% 
(9.12% ± 1.41% to 7.94% ± 1.18%) in the HbA1c value was observed. Further 
HbA1c improvements were documented in patients followed for 6 months after 
clinical enrollment. This study revealed that a pharmacist’s intervention can have a 
positive impact on patients’ therapy outcomes (Collier & Baker, 2014).  
To measure the effects of a pharmacist-run medication management program on 
medication adherence, glycemic control, and total health care expenditures, Scott & 
White Health Plan (SWHP) claims data were evaluated. High-risk patients (n = 46) 
having HbA1c greater than 7.5% and spending more than $600 for their medications 
were included in this study. A control group was also identified. The study was 
conducted for 1 year. Patients in the intervention group showed greater improvement 
(9.5% to 8.2%) in HbA1c values than controls, who moved from a baseline of 9.5% to 
8.7% at the end of the study. The total monthly health care costs were increased in 
both groups, but the increase was lower in the intervention group. Patients in the 
